Ceapro Inc V.CZO

New 52-week high for S&P Biotech ETF

[prophetoffactz]

96.18+1.43 (+1.51%)

As of 09:35AM EST. Market open.

Up 50% in four months.

Gilles did his part to scoop biotech assets up below cash after the worst biotech bear market in history. We may now be on the cusp of a multi-year breakout.

 

[lscfa]

Wainwright did not cut AEZS target price from $28 to $15 based on valuation multiples of the biotech sector. It slashed the target due to co. specific fundamentals.

[prophetoffactz]

At the bottom of the biotech market. The market is up a stunning 50% since the bottom and assets are valued in the context of the market and the other options available. We are in a different world and on the cusp of a potentia multi-year breakout in biotech. Also H.C. Wainwright had no idea what the new diagnostic deal will look like. That should be announced soon with the pediatric data. Gilles

[prophetoffactz]

Breakout... 97.02+2.27 (+2.40%) As of 09:35AM EST. Market open.

[prophetoffactz]

Last time the S&P Biotech ETF was trading at this level looks about April 4, 2022 judging by the Stockhouse chart. AEZS was US$9.34 or about 400% higher. It's a different situation now but when AEZS announces its clinical pediatric data and a diagnostic deal(s) as well as potential clinical trial 'go' decisions for its pipeline(eg. AIM Biologicals) and the clinical path forward it